TY - JOUR
T1 - Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy
T2 - A propensity score-matched, nationwide, population-based cohort study
AU - Chen, Tsung Ming
AU - Lin, Kuan Chou
AU - Yuan, Kevin Sheng Po
AU - Chang, Chia Lun
AU - Chow, Jyh Ming
AU - Wu, Szu Yuan
N1 - Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2018/10
Y1 - 2018/10
N2 - Background: No large-scale, head-to-head, phase III, randomized, controlled trial with an adequate sample size has investigated the effect of concurrent low-dose (LD) or high-dose (HD) cisplatin with radiotherapy on nasopharyngeal cancer (NPC). Thus, we conducted a propensity-score-matched, nationwide, population-based cohort study in Taiwan to investigate the outcomes of LD-concurrent chemoradiotherapy (CCRT) or HD-CCRT with intensity-modulated radiotherapy (IMRT) in patients with advanced NPC. Methods: In this study, patients were categorized into 2 groups according to their chemotherapy regimen: HD-CCRT and LD-CCRT groups. Results: We enrolled 1968 patients (328 and 1640 in the LD-CCRT and HD-CCRT groups, respectively) who had received CCRT with IMRT. According to both univariate and multivariate Cox regression analyses, a hazard ratio (95% confidence interval) of 0.75 (0.54-1.06, P = .103) was derived for the HD-CCRT group. Conclusion: LD-CCRT or HD-CCRT with IMRT can be a standard treatment that can prolong the survival of patients with advanced NPC.
AB - Background: No large-scale, head-to-head, phase III, randomized, controlled trial with an adequate sample size has investigated the effect of concurrent low-dose (LD) or high-dose (HD) cisplatin with radiotherapy on nasopharyngeal cancer (NPC). Thus, we conducted a propensity-score-matched, nationwide, population-based cohort study in Taiwan to investigate the outcomes of LD-concurrent chemoradiotherapy (CCRT) or HD-CCRT with intensity-modulated radiotherapy (IMRT) in patients with advanced NPC. Methods: In this study, patients were categorized into 2 groups according to their chemotherapy regimen: HD-CCRT and LD-CCRT groups. Results: We enrolled 1968 patients (328 and 1640 in the LD-CCRT and HD-CCRT groups, respectively) who had received CCRT with IMRT. According to both univariate and multivariate Cox regression analyses, a hazard ratio (95% confidence interval) of 0.75 (0.54-1.06, P = .103) was derived for the HD-CCRT group. Conclusion: LD-CCRT or HD-CCRT with IMRT can be a standard treatment that can prolong the survival of patients with advanced NPC.
KW - High-dose concurrent chemoradiotherapy
KW - Intensity-modulated radiotherapy
KW - Low-dose concurrent chemoradiotherapy
KW - Nasopharyngeal cancer
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85038878760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038878760&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2017.12.004
DO - 10.1016/j.radonc.2017.12.004
M3 - Article
C2 - 29277447
AN - SCOPUS:85038878760
SN - 0167-8140
VL - 129
SP - 23
EP - 29
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 1
ER -